Related Experiment Video
Updated: May 10, 2025
06:38
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
2.2K
Updates in immunomodulator therapy in ocular surface inflammatory diseases
Ali Khodor1, Luis A Rodriguez-Gutierrez, Raul E Ruiz-Lozano
1Bascom Palmer Eye Institute, University of Miami, Miami, Florida, USA.
Current Opinion in Ophthalmology
|April 25, 2025
Summary
Novel immunomodulatory therapies offer promising alternatives to corticosteroids for ocular surface inflammatory disorders. Targeted agents and biologics are advancing treatment for conditions like allergic conjunctivitis and oGVHD.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Ocular surface inflammatory disorders (OSIDs) present complex immune challenges.
- Corticosteroids, a traditional therapy, have limitations.
- There is a need for novel, steroid-sparing immunomodulatory options.
Purpose of the Study:
- To review novel, steroid-sparing immunomodulatory treatments for OSIDs.
- To explore advancements beyond traditional therapies like corticosteroids.
Main Methods:
- Literature review of recent advancements in immunomodulatory therapies for OSIDs.
- Analysis of emerging agents targeting specific immune pathways.
Main Results:
- Immunomodulatory therapies have evolved to include JAK inhibitors (e.g., ruxolitinib) and biologics (e.g., dupilumab, upadacitinib).
- JAK inhibitors and combination therapies show promise for oGVHD.
- Rituximab and IVIg are effective for cicatrizing conjunctivitis.
- Novel targets include chemokine receptor blockers, Treg modulation, and micro-RNA therapeutics.
Conclusions:
- The future of OSID therapy involves refining current treatments and developing targeted biologics.
- These advancements aim to improve efficacy and safety for sight-threatening ocular conditions.
Keywords:
anterior segment diseasecicatrizing diseaseimmunomodulatory therapyocular surface inflammatory disorderMore Related Videos
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
358
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
358
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
01:29Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80